 Intrapleural cisplatin cytarabine management malignant pleural effusions Lung Cancer Study Group trial Malignant pleural effusions common significant problem patients advanced malignancies Pleurodesis tetracycline agents usual treatment malignant pleural effusions contrast approach intrapleural chemotherapy potential advantage underlying malignancy addition effusion Intracavitary cisplatin-based chemotherapy cytotoxic safe effective intraperitoneal route ovarian cancer malignant mesothelioma little previous experience intrapleural cisplatin-based chemotherapy part planned series trials malignant mesothelioma Lung Cancer Study Group intrapleural cisplatin cytarabine patients malignant pleural effusions variety solid tumors April November patients symptomatic untreated malignant pleural effusions study single dose cisplatin cytarabine mg pleural space chest tube Patients toxicity response hours weeks recurrence effusion complete response CR Partial response PR decrease amount effusion serial chest radiographs patient reversible grade renal toxicity patients hematologic toxicity patients cardiopulmonary toxicity overall response rate CR PR weeks patients median length response months CR months PR outcome trial regimen subsequent trials malignant pleural mesothelioma